Updates

Get Alerts
With a free MyAccess profile, you can sign up to receive an email alert when new content is published on this site.
February 1, 2018 | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2016 New and Noteworthy FDA Approvals (Part 3) Nelda Murri, PharmD, MBA
February 1, 2018 | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2016 New and Noteworthy FDA Approvals (Part 2) Nelda Murri, PharmD, MBA
February 1, 2018 | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2016 New and Noteworthy FDA Approvals (Part 1) Nelda Murri, PharmD, MBA
February 1, 2018 | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2014 New and Noteworthy FDA Approvals Nelda Murri, PharmD, MBA
February 1, 2018 | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2013 New and Noteworthy FDA Approvals (Part 2) Nelda Murri, PharmD, MBA
February 1, 2018 | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2013 New and Noteworthy FDA Approvals (Part 1) Nelda Murri, PharmD, MBA
February 1, 2018 | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2012 New and Noteworthy FDA Approvals (Part 2) Nelda Murri, PharmD, MBA
February 1, 2018 | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2012 New and Noteworthy FDA Approvals (Part 1) Nelda Murri, PharmD, MBA
February 1, 2018 | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2011 New and Noteworthy FDA Approvals (Part 2) Nelda Murri, PharmD, MBA
February 1, 2018 | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2011 New and Noteworthy FDA Approvals (Part 1) Nelda Murri, PharmD, MBA
December 2, 2015 | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update Update 62-1 Idelalisib: A First-in-Class Specific Inhibitor of PI3Kδ for the Treatment of B-cell lymphomas (ABSTRACT) Randa Hilal-Dandan, PhD